Impact of Ultra-processed Foods in a Population of Patients With Chronic Rheumatic Diseases (Rheumatoid Arthritis, Spondyloarthritis, Osteoarthritis).
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Hospices Civils de Lyon
- Enrollment
- 240
- Locations
- 1
- Primary Endpoint
- Describe the consumption of ultra-processed foods in patients with chronic inflammatory rheumatism
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
Ultra-processed foods (UPF) represent one of the mainstays of today's diet. They are defined by the NOVA classification system. It was demonstrated that UPF consumption was associated with activity of inflammatory bowel diseases with underlying mechanisms not fully identified yet. It is suspected that UPF constituents could modify the gut microbiota, increase intestinal barrier permeability and directly engage immune surveillance systems, effects that could individually or synergistically increase the risk of immunomediated diseases. As some pathophysiological mechanisms are shared among IBD and rheumatic diseases, we have wondered if UPF consumption could be associated with increased risk of rheumatic disease and/or with their activity.
Our primary aim will be to study the pattern of UPF consumption in patients with rheumatic diseases. Our secondary objectives will be to study the activity of diseases according to UPF consumption.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age \> 18 years
- •chronic rheumatic disease (Rheumatoid arthritis, spondyloarthritis, osteoarthritis)
- •ability to perform questionnaires
Exclusion Criteria
- •Judicial protection measure
- •Refusal to participate in the study
- •Suffering from 2 rheumatic disease simultaneously
Outcomes
Primary Outcomes
Describe the consumption of ultra-processed foods in patients with chronic inflammatory rheumatism
Time Frame: At baseline
Describes the consumption of ultra-processed foods in patients with chronic inflammatory rheumatism using a self-assessment questionnaire (Score UPF Nova Screener) completed at baseline, 6 and 12 months.